Lawmakers are looking to break up massive health care conglomerates that manage nearly 80 percent of prescriptions.

The PBMs are charged with incentivizing manufacturers to inflate insulin list prices, restricting patients’ access to more ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The biggest factors in the higher cost of American health care are not insurance profits but high prices charged by providers of inpatient and outpatient care and higher administrative costs, ...

Before 2022, Congress tied Medicare’s hands and would not allow it to negotiate prices for medicines like insulin, cancer ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Early GLP-1s were developed as diabetes treatments owing to their ability to stimulate insulin production, with weight loss ...

Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

Any sort of list or ranking is fraught with subjectivity, and perhaps none more so than ranking the 100 greatest human ...

To receive the full newsletter in your inbox for free sign up here) An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...